Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EXASNASDAQ:HALONASDAQ:LGNDNASDAQ:RGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEXASExact Sciences$45.46-0.3%$45.34$39.97▼$72.83$8.44B1.142.61 million shs1.09 million shsHALOHalozyme Therapeutics$60.49+2.1%$60.50$37.97▼$66.00$7.47B1.321.44 million shs992,970 shsLGNDLigand Pharmaceuticals$108.07-0.4%$108.78$69.51▼$129.90$2.08B1.07120,497 shs102,809 shsRGENRepligen$144.75-0.3%$139.80$102.97▼$182.52$8.13B1.27712,103 shs439,931 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEXASExact Sciences0.00%+9.33%+1.04%-18.79%-28.12%HALOHalozyme Therapeutics0.00%+2.89%-6.19%+8.46%+54.63%LGNDLigand Pharmaceuticals0.00%+2.95%-1.49%-6.05%+52.21%RGENRepligen0.00%+11.35%+5.56%-12.74%-13.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEXASExact Sciences4.3817 of 5 stars4.52.00.04.72.21.70.6HALOHalozyme Therapeutics3.9979 of 5 stars1.31.00.04.42.22.54.4LGNDLigand Pharmaceuticals4.3022 of 5 stars3.50.00.04.43.42.51.9RGENRepligen4.6099 of 5 stars3.33.00.04.52.83.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEXASExact Sciences 2.95Moderate Buy$69.2552.33% UpsideHALOHalozyme Therapeutics 2.60Moderate Buy$62.893.97% UpsideLGNDLigand Pharmaceuticals 3.00Buy$146.4335.49% UpsideRGENRepligen 2.57Moderate Buy$176.8222.15% UpsideCurrent Analyst Ratings BreakdownLatest LGND, EXAS, RGEN, and HALO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/25/2025HALOHalozyme TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00 ➝ $72.004/21/2025HALOHalozyme TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$55.00 ➝ $58.004/16/2025RGENRepligenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$170.00 ➝ $150.004/11/2025EXASExact SciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.004/10/2025EXASExact SciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$65.00 ➝ $55.004/10/2025EXASExact SciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$60.004/10/2025LGNDLigand PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$143.004/9/2025EXASExact SciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/28/2025EXASExact SciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$60.003/18/2025RGENRepligenEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageIn-Line$155.003/13/2025EXASExact SciencesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Perform$52.00(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEXASExact Sciences$2.76B3.06$5.17 per share8.79$12.93 per share3.52HALOHalozyme Therapeutics$1.02B7.36$4.90 per share12.35$2.95 per share20.51LGNDLigand Pharmaceuticals$167.13M12.47$4.43 per share24.39$40.39 per share2.68RGENRepligen$634.44M12.81$2.70 per share53.61$35.19 per share4.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEXASExact Sciences-$204.15M-$5.57N/A90.92N/A-37.29%-5.29%-2.45%5/1/2025 (Estimated)HALOHalozyme Therapeutics$281.59M$3.4317.649.730.4243.74%157.78%25.34%5/6/2025 (Estimated)LGNDLigand Pharmaceuticals$52.15M-$0.1643.0629.13N/A29.68%4.95%4.39%5/8/2025 (Estimated)RGENRepligen$35.60M-$0.51N/A61.334.54-4.64%4.21%2.94%4/29/2025 (Estimated)Latest LGND, EXAS, RGEN, and HALO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025LGNDLigand Pharmaceuticals$1.23N/AN/AN/A$37.84 millionN/A5/6/2025Q1 2025HALOHalozyme Therapeutics$0.98N/AN/AN/A$231.21 millionN/A5/1/2025Q1 2025EXASExact Sciences-$0.35N/AN/AN/A$688.58 millionN/A4/29/2025Q1 2025RGENRepligen$0.35N/AN/AN/A$163.65 millionN/A2/20/2025Q4 2024RGENRepligen$0.41$0.44+$0.03-$0.60$167.58 million$167.55 million2/19/2025Q4 2024EXASExact Sciences-$0.29-$0.06+$0.23-$4.67$701.45 million$713.42 million2/18/2025Q4 2024HALOHalozyme Therapeutics$1.17$1.19+$0.02$1.06$285.74 million$298.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEXASExact SciencesN/AN/AN/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ARGENRepligenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEXASExact Sciences0.972.151.93HALOHalozyme Therapeutics4.147.809.15LGNDLigand PharmaceuticalsN/A12.4911.81RGENRepligen0.2610.448.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEXASExact Sciences88.82%HALOHalozyme Therapeutics97.79%LGNDLigand Pharmaceuticals91.28%RGENRepligen97.64%Insider OwnershipCompanyInsider OwnershipEXASExact Sciences1.36%HALOHalozyme Therapeutics2.90%LGNDLigand Pharmaceuticals5.90%RGENRepligen1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEXASExact Sciences6,400185.76 million182.56 millionOptionableHALOHalozyme Therapeutics390123.53 million120.20 millionOptionableLGNDLigand Pharmaceuticals8019.28 million17.78 millionOptionableRGENRepligen2,02056.15 million55.36 millionOptionableLGND, EXAS, RGEN, and HALO HeadlinesRecent News About These CompaniesRepligen (RGEN) Projected to Post Earnings on TuesdayApril 27 at 1:43 AM | marketbeat.comRepligen Co. (NASDAQ:RGEN) Shares Acquired by Price T Rowe Associates Inc. MDApril 26 at 5:53 AM | marketbeat.comFirst Trust Advisors LP Has $41.10 Million Holdings in Repligen Co. (NASDAQ:RGEN)April 26 at 4:56 AM | marketbeat.comCANADA LIFE ASSURANCE Co Has $5.92 Million Stock Position in Repligen Co. (NASDAQ:RGEN)April 26 at 4:47 AM | marketbeat.comBrokerages Set Repligen Co. (NASDAQ:RGEN) PT at $176.82April 25 at 2:25 AM | americanbankingnews.comRepligen (NASDAQ:RGEN) Shares Gap Up - Still a Buy?April 24 at 12:15 PM | marketbeat.comEversept Partners LP Sells 109,527 Shares of Repligen Co. (NASDAQ:RGEN)April 24 at 7:09 AM | marketbeat.comWill Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report?April 23, 2025 | zacks.comRepligen Co. (NASDAQ:RGEN) Given Consensus Rating of "Moderate Buy" by BrokeragesApril 23, 2025 | marketbeat.comRepligen Co. (NASDAQ:RGEN) Receives a Consensus Rating of "Moderate Buy" from AnalystsApril 22, 2025 | kalkinemedia.comRepligen (RGEN) Reports Next Week: Wall Street Expects Earnings GrowthApril 22, 2025 | zacks.comQ2 Earnings Estimate for Repligen Issued By Leerink PartnrsApril 20, 2025 | marketbeat.comMarshall Wace LLP Has $59.34 Million Position in Repligen Co. (NASDAQ:RGEN)April 20, 2025 | marketbeat.comChamplain Investment Partners LLC Purchases 122,595 Shares of Repligen Co. (NASDAQ:RGEN)April 19, 2025 | marketbeat.comOsterweis Capital Management Inc. Buys 8,240 Shares of Repligen Co. (NASDAQ:RGEN)April 19, 2025 | marketbeat.comSynovus Financial Corp Acquires New Holdings in Repligen Co. (NASDAQ:RGEN)April 19, 2025 | marketbeat.comLeerink Partners Sticks to Their Buy Rating for Repligen (RGEN)April 19, 2025 | markets.businessinsider.comLegal & General Group Plc Lowers Stock Position in Repligen Co. (NASDAQ:RGEN)April 19, 2025 | marketbeat.comCanaccord Genuity Group Has Lowered Expectations for Repligen (NASDAQ:RGEN) Stock PriceApril 18, 2025 | marketbeat.comRepligen (NASDAQ:RGEN) Trading 4.3% Higher - Here's WhyApril 18, 2025 | marketbeat.comFederated Hermes Inc. Trims Stock Position in Repligen Co. (NASDAQ:RGEN)April 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonTop 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or HoldBy Thomas Hughes | April 14, 2025View Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or HoldBig Blue's Big Shift: IBM's Turnaround Bet on Cloud and AIBy Jeffrey Neal Johnson | April 7, 2025View Big Blue's Big Shift: IBM's Turnaround Bet on Cloud and AIRetail Data Shows Urgency in Auto Parts: These 3 Stocks Could WinBy Gabriel Osorio-Mazilli | April 22, 2025View Retail Data Shows Urgency in Auto Parts: These 3 Stocks Could WinLGND, EXAS, RGEN, and HALO Company DescriptionsExact Sciences NASDAQ:EXAS$45.46 -0.14 (-0.31%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$45.43 -0.03 (-0.07%) As of 04/25/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Halozyme Therapeutics NASDAQ:HALO$60.49 +1.24 (+2.09%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$60.50 +0.01 (+0.02%) As of 04/25/2025 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Ligand Pharmaceuticals NASDAQ:LGND$108.07 -0.48 (-0.44%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$108.18 +0.12 (+0.11%) As of 04/25/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Repligen NASDAQ:RGEN$144.75 -0.48 (-0.33%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$143.75 -1.00 (-0.69%) As of 04/25/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
